Form 4: Dianthus Director Sells $2.15M in Stock

Dianthus Therapeutics Director Paula Soteropoulos exercised options and sold 27,594 shares for approximately $2.15 million under a pre-arranged trading plan.

Summary

• Paula Soteropoulos, a Director of Dianthus Therapeutics, Inc. (DNTH), executed a pre-arranged trading plan.
• On March 24, 2026, she exercised stock options to acquire 27,594 shares of common stock at an exercise price of $8.44 per share.
• Concurrently, she sold all 27,594 shares of common stock at a price of $78.05 per share.
• The total proceeds from the sale amounted to approximately $2,153,687.70.
• The transactions were conducted under a Rule 10b5-1 trading plan adopted on December 23, 2025.
• Following these transactions, Paula Soteropoulos directly owns 0 shares of common stock and 1,198 stock options.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While it's an insider sale, it's a planned realization of gains from options, not necessarily a bearish signal, and reflects significant stock appreciation.

Positives

• The transaction was executed under a Rule 10b5-1 trading plan, indicating a pre-scheduled sale rather than a reaction to immediate news.
• The sale price of $78.05 is significantly higher than the exercise price of $8.44, indicating a substantial gain for the director.

Negatives

• A director selling a significant portion of their directly held shares (all 27,594 acquired through exercise) could be interpreted as a reduction in direct equity exposure.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider sales, particularly those executed under a Rule 10b5-1 plan, are common for executives and directors managing their personal portfolios and diversifying holdings. While a sale of this magnitude might draw attention, the pre-arranged nature suggests it is not a reaction to new, undisclosed negative information about Dianthus Therapeutics, Inc. (DNTH).

Comparison to Industry Standards

• StockSavvy.ai observes that insider transactions, especially option exercises followed by sales, are a standard practice for executive compensation and personal financial planning across various industries.
• For instance, similar transactions are frequently seen in biotech and pharmaceutical companies where executives often receive significant equity compensation.
• The substantial difference between the exercise price ($8.44) and the sale price ($78.05) reflects a significant appreciation in the company's stock value since the options were granted, a common outcome in successful growth-stage companies like those in the biotech sector, comparable to gains seen by executives at companies such as Moderna or BioNTech during periods of strong performance.

Stakeholder Impact

• Shareholders: May observe a director reducing direct equity holdings, but the pre-planned nature mitigates immediate concern.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Recommendation

While a director selling shares can sometimes be a negative signal, this transaction was pre-planned under a Rule 10b5-1 plan and represents the realization of gains from vested stock options. The significant profit margin between exercise and sale price indicates strong stock performance. Without additional company-specific news, this single insider transaction is not a strong enough signal to warrant a 'buy' or 'sell' recommendation, suggesting a 'hold' position for existing investors to await further fundamental updates.

Keywords

Dianthus Therapeutics, DNTH, SEC Form 4, Insider Trading, Stock Sale, Stock Option Exercise, Paula Soteropoulos, Director, Rule 10b5-1